New combo targets Hard-to-Treat melanoma

NCT ID NCT03131908

Ongoing Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether combining an experimental drug (GSK2636771) with the immunotherapy pembrolizumab (Keytruda) can help control metastatic melanoma in patients whose tumors have lost a protein called PTEN. The trial involves up to 41 adults with advanced melanoma that hasn't responded to prior treatment. Researchers will first find the safest dose of the combination, then measure how well it shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GSK2636771 (a PI3K-beta inhibitor) and pembrolizumab (Keytruda, an immunotherapy)
What this could lead to: If this combination works, it could offer a new treatment option for people with a specific type of melanoma that has not responded to standard therapies.
What could go wrong: This is an early-phase trial with only 27 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MELANOMA AND OTHER MALIGNANT NEOPLASMS OF SKIN are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

melanoma metastatic melanoma skin cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MELANOMA AND OTHER MALIGNANT NEOPLASMS OF SKIN METASTATIC MELANOMA

Contacts and locations

Locations

University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.